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Objectives: The current study aimed to describe the incidence of abnormal liver function tests
(LFTs) in pregnant COVID-19 patients, explore the association between LFTs with current
medication, and provide a reference for medical therapy of pregnant patients with COVID-19.
Material and methods: This retrospective single tertiary center cohort study included 122
pregnant patients with confirmed COVID-19 admitted and treated from April 1, 2020, to May
31, 2020. We defined abnormal LFTs as the elevation of the following liver enzymes in serum
per our hospital’s laboratory reference range standards: AST > 35 U/L, ALT > 35 U/L, and
TBIL > 1.2 mg/dL. We evaluated patients for demographic and clinical features, laboratory
parameters, medications, and hospital length of stay (LOS).
Results:  Patients  in  this  cohort  had  clinical  presentations  of  fever  (84.4%),  dry  cough
(78.6%), and shortness of breathing (6.5%). In total, 17 (13.9%) patients had abnormal LFTs
during hospitalization.  Critically ill  patients  were  three-fold higher  in  the abnormal  LFTs
group (11.8%) than in the normal LFTs group (3.8%, p = 0.16). The proportion of patients
who used hydroxychloroquine and lopinavir/ritonavir  were significantly higher  in  patients
with abnormal LFTs (88.2% and 35.3%, respectively) than those with normal LFTs (62.9%
and 15.2%, p = 0.04 and p = 0.04,  respectively).  The hospital  length of stay (LOS) was
significantly longer in the abnormal LFTs group (8.2 ± 5.8 days) than in the normal LFT
group (6.0 ± 2.8 days, p = 0.02).
Conclusions: SARS-CoV-2 may induce liver injury and the LFT abnormality was generally
mild in pregnant  patients with COVID-19. Abnormal LFTs are associated with prolonged
hospital LOS. Drug use was the most crucial risk factor for liver injury during hospitalization.
The  use  of  lopinavir/ritonavir  and  hydroxychloroquine  were  significantly  higher,  and  the
course of treatment of these drugs was significantly longer in pregnant women with abnormal
LFTs than the patients with normal LFTs. Therefore, pregnant women with COVID-19 who
received antiviral treatment should be closely monitored for evaluating LFTs.
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INTRODUCTION
The coronoviridae family of viruses has risen as a global threat to public health and
can  cause  both  respiratory  and  multisystemic  diseases  in  numerous  human  species  and
humans [1,  2].  Of these,  severe acute  respiratory syndrome coronavirus-2 (SARS-CoV-2)
originated  in  Wuhan  City  in  Hubei  Province,  central  China,  was  responsible  for  the
Coronavirus Disease 2019 (COVID-19) in December 2019, and rapidly spread across the
globe [3]. As of August 2020, more than 20 million patients globally had been infected with
Covid-19,  and  more  than  700 000 deaths  are  associated  with  this  virus  [4].  Researchers
reported that approximately 15% of patients infected with COVID-19 progress severe health
complications, about 5–10% require intensive care unit  due to the severe pneumonia type
symptoms, and with 3–5% of high mortality risk [5].  As this  disease continues to  spread
sustainably and indiscriminately across the world, it is expected to see pregnant patients with
COVID-19 canvassed across all trimesters of gestation [6]. Therefore, further epidemiological
and clinical features should be clarified to enhance our perception of the virus’s correct extent,
develop diagnostic and treatment abilities and diminish its overall morbidity and mortality.   
COVID-19 patients typically present with fever, weakness, dry cough, and shortness
of breathing [7]. SARS-CoV-2 has also been associated with different degrees of liver injury
[8]. Previous studies reported that 14–76% of COVID-19 patients experience abnormal liver
function tests (LFTs), primarily increased levels of serum alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) [9, 10]. The extent and underlying mechanisms for liver
injury  in  COVID-19  patients  are  not  fully  understood,  but  the  pathogenesis  seems
multifactorial. The primary liver injury mechanism in COVID-19 patients is considered to be
the binding of SARS-CoV-2 to angiotensin-converting enzyme 2 (ACE2) receptor, which is
known as the host cell entry receptor and highly expressed cholangiocytes, and then damages
these  bile  duct  cells  [11].  Cholangiocytes  are  dynamic  players  in  many aspects  of  liver
physiology, including regeneration and innate and adaptive immune response mechanisms,
and the disruption of these cells’ functions induces a systemic inflammatory response leading
to hepatobiliary damage [12]. Moreover, an autopsy analysis of liver biopsy specimens from a
COVID-19 patient showed moderate microvesicular steatosis and mild inflammation in the
portal  and lobular area,  suggesting that the liver injury might be caused by SARS-CoV-2
infection or drug-induced liver injury (DILI) [13]. Studies also indicated that this virus could
cause acute respiratory distress syndrome (ARDS) and multiple organ failure (MOF), driving
to hepatic ischemia and hypoxia reperfusion injury in severe COVID-19 patients [14, 15].
Till  present,  a  few data  exist  in  the  literature  that  has  elaborately  investigate  the
prevalence  and  severity  of  abnormal  LFTs,  their  association  with  baseline  LFTs  before
COVID-19  hospitalization,  and  clinical  characteristics  of  liver  failure  among  pregnant
patients  with  COVID-19.  Hence,  the  current  study  aimed  to  describe  the  incidence  of
abnormal LFTs in pregnant COVID-19 patients, explore the association between LFTs with
current medication, and provide a reference for medical therapy of pregnant patients with
COVID-19.
MATERIAL AND METHODS
This retrospective single tertiary center cohort study included 122 pregnant patients
with confirmed COVID-19 admitted and treated from April 1, 2020, to May 31, 2020, at XX
Hospital  isolation  ward.  All  patients  had  an exposure  history and clinical  presentation  of
COVID-19, including respiratory symptoms or fever. We diagnosed patients with COVID-19
based on the World Health Organization (WHO) interim guidance [16]. The ethics committee
of the hospital approved the study (approval date: 10.06.2020, approval number: 2020.06.67).
We  detected  SARS-CoV-2  nucleic  acid  in  all  patients  by  real-time  nasopharyngeal  swab
polymerase  chain  reaction  (PCR).  Pregnant  COVID-19  patients  underwent  clinical
assessment of vital signs and symptoms, laboratory analysis, and radiologic chest evaluation
at admission. We performed a chest X-ray and/or computed tomography (CT) for pneumonia
diagnosis. As expected, concerns relating to the possible teratogenic impacts to the fetus from
radiation exposure are inevitable. The accepted cumulative dose of ionizing radiation in the
course of pregnancy is 5 rad, and no single diagnostic examination exceeds this upper limit.
The exposure amount to the fetus from a two-view chest X-ray of the pregnant woman is
0.00007 rad, and chest CT (10 slices with a slice thickness of 10 mm) exposes the fetus to <
0.1  rad  [17].  Thus,  Wang  et  al.  suggested  that,  if  indicated,  in  a  pregnant  patient  with
suspected  COVID-19,  chest  X-ray  and  chest  CT  can  be  conducted  safely  [18].  Before
undergoing chest X-ray and CT examinations, pregnant patients with COVID-19 signed an
informed consent form and had their lower abdomen and pelvis covered with a lead blanket.
We classified pregnant patients into mild or severe cases based on the results from symptoms,
clinical findings, and chest radiography [10]. We identified patients with mild symptoms (i.e.,
fever, dry cough, expectoration) with or without mild changes on chest imaging as mild cases.
We  defined  mild  changes  in  chest  radiography  by  multiple  small  patchy  shadows  and
interstitial  changes,  primarily  in  the  outer  region  of  the  lung  and  below  the  pleura.  We
described  patients  with  severe  pneumonia  by  any  of  the  following  findings’ presence:
increased respiration rate (RR, ≥ 30/minute), hypoxia (resting oxygen saturation ≤ 93%), the
partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤ 300 mmHg in blood gas
analysis,  or  respiratory or  other  organ failure  occurrence  that  requires  intensive  care  unit
(ICU) admission, or shock.   
Since there was no standard guidance on drug choice, therapeutic management was
accommodated according to the clinical findings and guidelines [16]. All pregnant patients
received supportive treatments, including intravenous fluid supplementation and maintenance
of electrolyte and acid-base homeostasis, and a prophylactic dose of lower molecular weight
heparin for preventing thromboembolic complications (LMWH) [19]. We closely monitored
vital signs and finger oxygen saturation and gave oxygen treatment to hypoxemic patients.
Since no antiviral therapy or antibiotic regimen was accepted for COVID-19 treatment, we
treated  patients  with  lopinavir/ritonavir,  hydroxychloroquine,  or  azathioprine  [20].  The
decision of antiviral treatment regimen and/or antibiotic regimen was based on the infectious
disease specialist’s discretion.     
We  excluded  patients  with  gestational  hypertensive  disorders,  HELLP syndrome,
intrahepatic  cholestasis  of  pregnancy,  pre-existing  liver  disease,  other  infections,  and  co-
existing morbidities, including renal disease, collagen vascular disease, chronic hypertension,
known malignancy, and ischemic heart disease.
Age, gestational week, gravida, parity, and BMI were obtained by examining patients’
medical  records.  The  gestational  week  was  examined  by  sonographic  measurement  and
confirmed according to the last menstrual period and a first-trimester ultrasound exam [21].
The CBC values of the patients were measured with Mindray BC 6800, an automatic blood
counting device using laser and impedance measurement techniques. Hemoglobin (Hb), white
blood cell count (WBC), neutrophil count, lymphocyte count, platelet (PLT) count, D-Dimer,
ferritin, C-reactive protein (CRP), AST, ALT, total bilirubin (TBIL), direct bilirubin, indirect
bilirubin, amylase, and lipase values were all derived from patient' medical files. 
As COVID-19 is  a  recently identified  infectious  disease,  there is  no consensus  or
guidance on liver injury definition and classification. Therefore, abnormal LFTs were defined
as  the  elevation  of  the  following  liver  enzymes  in  serum  per  our  hospital’s  laboratory
reference range standards: AST > 35 U/L, ALT > 35 U/L, and TBIL > 1.2 mg/dL. We obtained
admission values of LFTs and peak values of aminotransferases during hospitalization.   
We discharged  pregnant  patients  treated  when the  symptoms  and  clinical  findings
improved  significantly,  with  no  fever  for  at  least  three  days,  and  obvious  absorption  of
inflammation  in  pulmonary  imaging.  Patients  who  did  not  meet  the  discharge  criteria
continued hospitalization for treatment and close follow-up. We also recorded the hospital
length of stay (LOS). We followed up on the patient outcomes until August 31, 2020. The
delivery mode was determined by standard obstetric indications [22].
Statistical analysis  
Continuous  variables  were  presented  as  means  ±  standard  deviations  if  normally
distributed  and  medians  [interquartile  ranges  (IQRs)]  if  not  normally  distributed,  while
categorical  variables  were  given  as  percentages.  The  chi-squared  (χ²)  test  was  used  to
compare categorical variables between the groups, while the Kolmogorov–Smirnov test was
employed to assess  whether  the variables  were normally distributed.  A Student’s  t-test  or
Mann–Whitney U test  was used to compare the continuous variables  between the groups
according  to  whether  they  were  normally  distributed  or  not.  Spearman's  rho correlation
coefficient was calculated to describe the degree of correlation between the parameters. In
order  to  determine  the  independent  predictors  of  liver  dysfunction,  variables  found to be
associated at a p<0.1 level according to univariate analysis, were included in the multivariate
logistic regression analysis by using the Backward LR method with the results reported as the
odds ratios (OR) and 95% confidence intervals (CI). The threshold of statistical significance
was  established  at  p<0.05.  All  statistical  analyses  were  performed  using  the  Statistical
Package for the Social Sciences version 24.0 software program (IBM Corp., Armonk, NY,
USA). 
RESULTS
During  the  study  period,  a  total  of  134  pregnant  women  with  COVID-19  were
admitted to our hospital. After applying the exclusion criteria and withholding patients with
missing medical records, 122 patients were included in our study.
Patients in this cohort had clinical presentations of fever (84.4%), dry cough (78.6%), and
shortness of breathing (6.5%). There were two (1.6%) pregnant patients with abnormal LFTs
on  admission.  One  of  them  progressed  to  severe  pneumonia  during  hospitalization  and
required  ICU  admission.  Of  patients  with  normal  baseline  LFTs,  15  patients  developed
elevated LFTs during hospitalization. One of them suffered from severe pneumonia and was
admitted to ICU. In total,  17 (13.9%) patients  had abnormal LFTs during hospitalization.
Critically ill patient rates were three-fold higher in the abnormal LFTs group (11.8%) than in
the normal LFTs group (3.8%). This difference was not statistically significant due to the low
sample size (p = 0.16).  All  patients  were discharged from the hospital  by June 18th.  No
patient died in our study cohort.       
The  demographic  variables,  clinical  characteristics,  and  the  perinatal  outcomes  of  the
participants  were  summarized  in  Table  1.  The  mean  age  was  significantly  higher  in  the
abnormal LFTs group (33.2 ± 6.1 years) than in patients with normal LFTs (28.1 ± 6.6 years).
There were no significant differences between the two groups in terms of gravidity, parity,
maternal weight, height, previous history of abortion, and the gestational week at admission.
The proportion of patients who used hydroxychloroquine and lopinavir/ritonavir were
significantly higher in patients with abnormal LFTs (88.2% and 35.3%, respectively) than
those  with normal  LFTs  (62.9% and 15.2%,  p = 0.04  and p = 0.04,  respectively).  Also,
patients  with  elevated  LFTs  received  significantly  longer  duration  of  treatment  with
hydroxychloroquine (4.7 ± 2.1 days) and lopinavir/ritonavir (2.7 ± 4.1 days) than those with
normal  LFTs (3.0  ± 2.5  days  and 0.7 ±  2.1 days,  p  = 0.01  and p  < 0.01,  respectively).
According to this, the hospital LOS was significantly longer in the abnormal LFTs group (8.2
± 5.8 days) than in the normal LFTS group (6.0 ± 2.8 days, p = 0.02).
We presented the laboratory parameters of the study population in Table 2. The peak
AST value on admission was 40 U/L, during hospitalization was 207 U/L. The peak ALT
value on admission was 37 U/L, during hospitalization was 200 U/L. AST and ALT elevations
were generally (82.3%) mild, defined as < 5 times the upper reference limit. There were no
significant differences between the groups in terms of neutrophil count, lymphocyte count,
CRP,  and  D-Dimer  value.  Serum  ferritin  level  was  significantly  higher  in  patients  with
elevated LFTs (243.6 ± 642 ng/mL)  than in the normal LFTs group (48.9 ± 50 ng/mL, p <
0.01). Platelet count was demonstrated to be significantly higher in patients with abnormal
LFTs (305 ± 169 (/mm3 ×103) than those in patients with normal LFTs (231 ± 71/mm3 × 103, p
< 0.01).
We  showed  factors  that  were  found  to  be  independently  associated  with  liver
dysfunction in univariate analysis and multivariate logistic regression analysis in Table 3. On
univariate  analysis,  maternal  age,  serum  ferritin  level,  serum  platelet  level,  parity,
hydroxychloroquine use, and lopinavir/ritonavir use were associated with LFTs abnormality. 
DISCUSSION
The  current  study  demonstrates  the  results  of  LFTs  and  clinical  outcomes  in
hospitalized pregnant  patients  with confirmed SARS-CoV-2 infection in a tertiary referral
hospital. In our study cohort, 13.9% of pregnant patients with COVID-19 had elevated LFTs
during hospitalization. Also, the pooled incidence of elevated aminotransferases determined
during hospitalization appeared to be higher than that of at admission (1.6%), suggesting the
disease progression and the toxicity of drugs used during hospitalization may both contribute
to liver injury.
Rabaan et al. stated that SARS-CoV-2 shares similarities in terms of pathogenicity and
structure  with  other  coronaviruses,  including  SARS-CoV and  MERS-CoV [23].  A study
during the SARS outbreak in  2004 reported that  abnormal LFTs were common (70%) in
patients with SARS and might be associated with virus replication in the liver [24]. Also, liver
specimens  of  SARS autopsies  have  demonstrated  hepatocyte  mitoses,  fatty  degeneration,
central  lobular  necrosis,  and  lymphocytic  infiltration,  suggesting  that  SARS-CoV-2  can
damage the liver tissue [25].
The  liver  plays  an  essential  role  in  host  defense  against  microorganisms  and  is
frequently involved in most systemic infections as it receives a dual blood supply from the
systemic and portal circulation. Various studies stated abnormal aminotransferase levels in
COVID-19 patients and abnormal LFTs are common in hospitalized COVID-19 patients [10,
12,  26,  27].  The prevalence  of  AST elevations  ranged between 4–53%,  and that  of  ALT
elevations ranged between 4–33% among COVID-19 patients in Chinese cohorts [26]. Sultan
et al. reported that the pooled prevalence estimates of elevated LFTs were 15.0% [28]. Fan et
al.  found significantly higher  (37.2%) abnormal  LFTs  than previously reported  rates,  and
elevated liver cell injury markers (AST, ALT) are more common. They suggested that liver
damage in COVID-19 patients might be directly induced by the liver cells’ viral infection
[29].  Hundt  et  al.  concluded  that  since  the  ACE2  receptor  is  dominantly  expressed  in
cholangiocytes than in hepatocytes,  the primary mechanism of liver injury is not due to the
cytopathic  effect  of  SARS-CoV-2  [27].  In  our  study,  13.9% of  pregnant  patients  during
hospitalization  had  abnormal  LFTs.  We  also  found  that  AST and  ALT  elevations  were
generally mild (1–2x the upper limit of normal). Likewise, Bertolini et al. reported that mild
elevations  of  ALT  and  AST  were  often  detected  observed  in  COVID-19  patients  on
admission, and this elevation did not drive to notable liver dysfunction [26].    
The  liver  is  the  major  organ for  drug metabolic  processes  and detoxification,  and
maintenance  of  function  is  crucial  to  participate  in  all  feasible  COVID-19  treatment
modalities.  Since  an  effective  antiviral  agent  for  COVID-19 has  not  been developed yet,
supportive and symptomatic therapies are essential. Also, antiviral drugs previously utilized to
treat other coronavirus infections have been considered as the first choice to treat COVID-19
patients  [30].  All  these  drugs  are  used  for  the  treatment  or  management  of  COVID-19
patients,  including  antiviral  drugs  (lopinavir/ritonavir,  hydroxychloroquine),  antibiotics,
antipyretics  (acetaminophen),  corticosteroids,  and  herbal  medicines  are  potentially
hepatotoxic [26]. Fan et al.  reported that the proportion of patients who were treated with
lopinavir/ritonavir was significantly higher in patients with liver injury than in patients with
sustained normal  LFTs  [29].  Wu et  al.  stated  that  compared  with  patients  suffering  mild
clinical  signs and symptoms, severe COVID-19 patients require  longer antiviral  treatment
duration and multiple drug combinations. The number of drugs used ≥ 3 might be associated
with liver injury  [31]. In our study, the use of lopinavir/ritonavir and hydroxychloroquine
were significantly higher,  and treatment  durations of  these medications were significantly
longer  in  the  abnormal  LFTs  group than  in  the  normal  LFTs  group.  We also  found that
abnormal  LFTs  during  hospitalization  are  associated  with  prolonged  hospital  LOS.  This
finding might  be due to the toxicity of drugs used during hospitalization and the clinical
course of the disease.
Regardless of the mechanisms implicated in the liver injury of COVID-19 patients,
immune-mediated  pathway activation  considers  to  be  crucial  [12].  Virus  particles  spread
through the respiratory mucosa, and then infect other cells, which induces a cytokine storm in
the  body  and  generates  a  series  of  immune  responses  [32].  COVID-19  patients  present
significant inflammatory marker activation,  including neutrophils, CRP, and cytokines that
might contribute to pulmonary and extrapulmonary injuries  [12]. Cytokine storm syndrome
(CSS) is an uncontrolled or excessive proinflammatory cytokine release to external stimuli,
which is correlated with disease severity  [33]. Fan et al. found that patients with abnormal
LFTs had higher inflammatory markers, including procalcitonin and CRP, and higher fever
rates, which might be associated with the immune response following SARS-CoV-2 infection
[29]. However, Zhao et al. indicated that abnormal LFTs in mild COVID-19 patients may not
be associated with inflammatory status [34]. It was also considered that specific inflammation
induced by SARS-CoV-2 is more prone to induce abnormal LFTs than general inflammation
caused by other  microorganisms. We did not find any significant  differences between the
groups  regarding  neutrophil  count,  lymphocyte  count,  and  CRP.  However,  serum ferritin
levels were significantly higher in pregnant women with abnormal LFTs than in the group
with  normal  LFTs.  Kernan  et  al.  demonstrated  that  ferritin  is  a  pivotal  marker  of  and
pathogenic player in the inflammatory process through its signaling as a component of the
innate immune response and lymphocyte function modulation [35]. However, the accurate
mechanism by which ferritin contributes to the course of this disease remains elusive. 
The prevalence of pre-existing liver disease in patients with SARS-CoV-2 infection
varies from 1–11% [26]. Previous studies stated that COVID-19 patients with pre-existing
liver diseases might be more prone to suffer abnormal LFTs [10, 12, 29, 31]. Also, the highest
proportion of deaths in COVID-19 patients were detected in elderly patients with underlying
liver diseases [36]. Our study cohort consisted of reproductive-aged pregnant patients. We
also excluded patients with pre-existing liver diseases from this study. We consider that these
criteria could explain our lower rates of severe COVID-19 patients than the previous research.
Patients with abnormal LFTs during hospitalization had a significantly higher risk of
worsening  to  severe  COVID-19  than  patients  with  normal  LFTs.  Progressing  to  severe
pneumonia  describes  the  clinical  situation  with  a  high  mortality  rate  that  requires  ICU
admission or mechanical ventilation [10]. In this study, while  3.8% of patients with normal
LFTs  exacerbate  severe  COVID-19,  11.8%  of  pregnant  women  with  elevated
aminotransferases  progressed  to  severe  pneumonia.  However,  this  difference  was  not
statistically significant. We consider that the absence of significant difference was due to the
low sample size.    
There are some limitations to this study. This study has been designed retrospectively
and has the potential to contain limitations of such studies [37]. Because of the dependence on
information reported in the patient record, we could not identify risk factors for all pregnant
patients with COVID-19. We also evaluated abnormal LFTs rather than liver injury, because
the description of liver damage was unclear in pregnant patients with COVID-19. The main
strength  of  this  study is  that  a  few data  exist  in  the  literature  that  has  comprehensively
examine the prevalence and severity of abnormal LFTs.
CONCLUSIONS
We demonstrated that SARS-CoV-2 may induce liver injury and the LFT abnormality
was generally mild in pregnant patients with COVID-19. Abnormal LFTs are associated with
prolonged hospital LOS. Drug use was the most crucial risk factor for liver injury during
hospitalization.  The  use  of  lopinavir/ritonavir  and  hydroxychloroquine  were  significantly
higher, and the course of treatment of these drugs was significantly longer in pregnant women
with abnormal LFTs than the patients with normal LFTs. Therefore, pregnant women with
COVID-19 who received antiviral treatment should be closely monitored for evaluating LFTs.
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Age, years 28.8 ± 6.8 28.1 ± 6.6 33.2 ± 6.1 < 0.01
Height, cm 161.8 ± 5.9 161.7 ± 5.9 162.3 ± 6.1 0.71
Weight, kg 76.3 ± 12.8 75.6 ± 12.8 80.5 ± 12.6 0.18
Gravidity, n 2.7 ± 1.5 2.5 ± 1.4 3.3 ± 1.7 0.05
Parity, n 1.3 ± 1.2 1.2 ± 1.1 2.1 ± 1.6 < 0.01
Previous abortion, n (%) 30 (24.6) 27 (25.7) 3 (17.6) 0.47
Gestational  week  at
admission
29.4 ± 9.3 29.2 ± 9.4 30.6 ± 8.6 0.57
Birth weight, g 3115 ± 634 3173 ± 607 2741 ± 713 0.05
Hydroxychloroquine usage, n
(%)
81 (66.4) 66 (62.9) 15 (88.2) 0.04
Hydroxychloroquine  usage
time, days                          
3.3 ± 2.5 3.0 ± 2.5 4.7 ± 2.1 0.01
Lopinavir/Ritonavir usage, n 
(%)
22 (18) 16 (15.2) 6 (35.3) 0.04
Lopinavir/Ritonavir  usage
time, days
0.98 ± 2.5 0.7 ± 2.1 2.7 ± 4.1 < 0.01
Azithromycine usage, n (%) 24 (19.7) 19 (18.1) 5 (29.4) 0.28
Azithromycine time, days 0.84 ± 1.8 0.77 ± 1.8 1.2 ± 2.2 0.33
Severe disease, n (%) 6 (4.9) 4 (3.8) 2 (11.8) 0.16
Hospital length of stay, days 6.3 ± 3.4 6.0 ± 2.8 8.2 ± 5.8  0.02
















































































































































Table  3.  Univariable  and  multivariable  logistic  regression  analysis  for  determining  the
predictors of the liver dysfunction 
Univariate Multivariate*
Variables OR (95%CI) p OR (95%CI) p
Maternal age 1.116 (1.031–1.207) < 0.01 1.156 (1.044–1.281) < 0.01
Ferritin 1.010 (1.002–1.018) < 0.01 1.011 (1.002–1.020) 0.01
Platelet 1.007 (1.001–1.013) 0.02 1.008 (1.001–1.015) 0.02
†Parity 1.703 (1.145–2.532) 0.01
†Hydroxychloroquine 0.226 (0.049–1.040) 0.06
†Lopinavir/Ritonavir 3.034 (0.982–9.375) 0.05
* Multivariate logistic regression analysis by using Backward LR method
† Not included in multivariate analysis according to Backward LR method
